{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.30","value":"3.8"},{"groupId":"OG001","spread":"1.30","value":"3.8"},{"groupId":"OG002","spread":"1.28","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"149"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.93","value":"-0.1"},{"groupId":"OG001","spread":"1.21","value":"0.1"},{"groupId":"OG002","spread":"0.90","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"title":"Change at Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.44","value":"-0.7"},{"groupId":"OG001","spread":"1.60","value":"-0.8"},{"groupId":"OG002","spread":"1.52","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"90"}],"units":"Participants"}],"title":"Change at Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.44","value":"-0.9"},{"groupId":"OG001","spread":"1.53","value":"-1.2"},{"groupId":"OG002","spread":"1.56","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"title":"Change at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.49","value":"-0.9"},{"groupId":"OG001","spread":"1.68","value":"-1.1"},{"groupId":"OG002","spread":"1.35","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"title":"Change at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.61","value":"-0.9"},{"groupId":"OG001","spread":"1.69","value":"-1.1"},{"groupId":"OG002","spread":"1.41","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Change at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.31","value":"-0.8"},{"groupId":"OG001","spread":"1.70","value":"-1.2"},{"groupId":"OG002","spread":"1.39","value":"-0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Change at Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.44","value":"-1.1"},{"groupId":"OG001","spread":"1.61","value":"-1.0"},{"groupId":"OG002","spread":"1.07","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Change at Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.56","value":"-1.2"},{"groupId":"OG001","spread":"1.58","value":"-1.1"},{"groupId":"OG002","spread":"0.71","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Change at Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.26","value":"-0.8"},{"groupId":"OG001","spread":"1.37","value":"-0.9"},{"groupId":"OG002","spread":"0.71","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Change at Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"-0.5"},{"groupId":"OG001","spread":"1.28","value":"-0.6"},{"groupId":"OG002","spread":"0.58","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Change at Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.38","value":"-0.9"},{"groupId":"OG001","spread":"1.38","value":"-1.1"},{"groupId":"OG002","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.45","value":"-0.9"},{"groupId":"OG001","spread":"1.36","value":"-0.8"},{"groupId":"OG002","spread":"0.71","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.39","value":"-1.3"},{"groupId":"OG001","spread":"1.52","value":"-0.9"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG002","spread":"NA","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"-1.1"},{"groupId":"OG001","spread":"1.05","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.47","value":"-1.2"},{"groupId":"OG001","spread":"0.89","value":"-1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.82","value":"-2.0"},{"groupId":"OG001","spread":"1.53","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.53","value":"-1.3"},{"groupId":"OG001","spread":"1.00","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 17 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-2.0"},{"groupId":"OG001","spread":"1.00","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 18 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-3.0"},{"groupId":"OG001","spread":"2.12","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 19 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-3.0"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 20 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-3.0"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 21 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 22 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.85","value":"0.3"},{"groupId":"OG001","spread":"1.82","value":"0.1"},{"groupId":"OG002","spread":"1.58","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"title":"Change at End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.08","value":"-0.1"},{"groupId":"OG001","spread":"1.43","value":"0.5"},{"groupId":"OG002","spread":"1.34","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Change at 30 Day Follow Up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"220"},{"groupId":"OG002","value":"221"}],"units":"Participants"}],"description":"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: \"Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.\"","dispersionType":"Standard Deviation","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG001","title":"Phase 3:Doublet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG002","title":"Phase 3:Control Arm"}],"paramType":"MEAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants. Here, 'Number Analyzed' signifies number of participants evaluable for the specified timepoints. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row.","reportingStatus":"POSTED","timeFrame":"Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)","title":"(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet","type":"SECONDARY","unitOfMeasure":"Units on a scale"}